You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 291 No. 17, May 5, 2004 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Epilepsy
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Safety of Newer Antiepileptic Drugs

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Although Drs LaRoche and Helmers1 discussed many of the important safety issues for new antiepileptic drugs in their Scientific Review article, additional safety issues have arisen with topiramate and zonisamide since their initial approval. Some of these safety issues may be related to the ability of these drugs to inhibit the enzyme carbonic anhydrase.

For topiramate, a warning describing a syndrome of acute myopia with secondary angle-closure glaucoma associated with treatment was added to the product labeling in 2001.2 It is important to note that although this adverse event is uncommon, prompt discontinuation of topiramate is imperative and appears to reverse the process. In 2003, a further warning was added for oligohydrosis, which is characterized by deficient formation and secretion of sweat that can lead to life-threatening fevers and heat stroke. This adverse effect may be more significant in children than in adults treated with topiramate3 and . . . [Full Text of this Article]

Judith A. Racoosin, MD, MPH
racoosinj@cder.fda.gov

James F. Knudsen, PhD, MD
Division of Neuropharmacological Drug Products
Center for Drug Evaluation and Research
US Food and Drug Administration
Rockville, Md



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Safety of Newer Antiepileptic Drugs—Reply
Suzette M. LaRoche and Sandra L. Helmers
JAMA. 2004;291(17):2074.
EXTRACT | FULL TEXT  

The New Antiepileptic Drugs: Scientific Review
Suzette M. LaRoche and Sandra L. Helmers
JAMA. 2004;291(5):605-614.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.